classic
hodgkin
lymphoma
chl
compris
approxim
case
lymphoma
worldwid
curabl
multiag
chemotherapi
major
case
includ
patient
advanc
stage
diseas
abvd
regimen
doxorubicin
bleomycin
vinblastin
dacarbazin
current
wide
use
frontlin
treatment
patient
earli
advanc
stage
chl
altern
regimen
date
show
superior
overal
surviv
os
patient
human
immunodefici
viru
hiv
infect
increas
risk
chl
chl
driven
epsteinbarr
viru
ebv
approxim
case
includ
nearli
case
associ
hiv
infect
multipl
prognost
risk
factor
identifi
intern
prognost
score
ip
wide
use
provid
riskstratif
base
upon
clinic
risk
factor
patient
advanc
stage
diseas
chl
character
rel
small
proport
patholog
reedsternberg
rs
cell
within
reactiv
inflammatori
milieu
associ
state
increas
clinic
practic
point
abvd
doxorubicin
bleomycin
vinblastin
dacarbazin
wide
use
frontlin
regimen
treatment
earli
advanc
stage
classic
hodgkin
lymphoma
chl
fulmin
syndrom
character
pyrexia
shock
observ
earli
trial
bleomycin
occur
frequent
patient
lymphoma
past
decad
case
similar
fulmin
reaction
follow
abvd
report
thu
limit
literatur
regard
risk
factor
clinic
cours
manag
lifethreaten
syndrom
identifi
patient
experienc
febril
hypotens
reaction
follow
abvd
chemotherapi
institut
share
baselin
clinic
featur
includ
stage
ivb
diseas
high
risk
diseas
intern
prognost
score
male
gender
epsteinbarr
virusposit
chl
patient
experienc
fever
rigor
tachycardia
short
breath
hypoxia
elev
venou
lactat
onset
less
hour
complet
first
abvd
infus
patient
receiv
intraven
fluid
resuscit
corticosteroid
patient
requir
vasopressor
owe
refractori
hypotens
patient
requir
mechan
ventil
respiratori
failur
symptom
resolv
within
hour
case
two
patient
receiv
bleomycin
subsequ
cycl
patient
treat
avd
doxorubicin
vinblastin
dacarbazin
fulmin
reaction
observ
subsequ
cycl
clinician
awar
fulmin
febril
hypotens
reaction
seen
follow
abvd
treatment
chl
manag
intraven
corticosteroid
intens
support
care
associ
resolut
within
hour
onset
present
seri
cytokin
product
includ
increas
tumor
necrosi
factora
interleukin
il
macrophag
promin
compon
tumor
microenviron
higher
proport
cell
tumor
microenviron
seen
ebvposit
chl
comparison
ebvneg
case
high
proport
tumorassoci
macrophag
associ
inferior
outcom
bleomycin
antibodi
complex
deriv
streptomyc
sp
antineoplast
properti
owe
part
inhibit
dna
synthesi
earli
clinic
investig
bleomycin
demonstr
singleag
activ
multipl
solid
organ
malign
highest
singleag
respons
rate
hodgkin
lymphoma
fever
report
patient
follow
singleag
bleomycin
typic
occur
first
dose
observ
frequent
patient
chl
compar
solid
organ
malign
fever
typic
selflimit
review
first
patient
treat
singleag
bleomycin
case
fulmin
fever
associ
hypotens
cardiorespiratori
collaps
lead
death
report
patient
lymphoma
preclin
studi
bleomycin
shown
provok
fever
dosedepend
manner
rabbit
onset
hour
administr
supernat
cultur
human
rabbit
leukocyt
bleomycin
induc
febril
respons
shorter
latenc
suggest
cytokinemedi
effect
subsequ
case
fatal
lifethreaten
febril
hypotens
reaction
patient
lymphoma
treat
bleomycin
part
multiag
therapi
report
includ
patient
febril
hypotens
reaction
follow
treatment
abvd
associ
tumor
lysi
syndrom
tl
markedli
elev
serum
present
case
patient
chl
experienc
fulmin
febril
hypotens
reaction
shortli
first
dose
abvd
similar
baselin
clinic
featur
includ
ebvposit
diseas
describ
clinic
cours
case
identifi
survey
lymphoma
faculti
institut
institut
review
board
approv
obtain
case
seri
patient
patient
year
old
initi
present
progress
worsen
left
inguin
lymph
node
enlarg
fever
malais
night
sweat
weight
loss
signific
past
medic
histori
physic
examin
signific
temperatur
f
palpabl
spleen
tip
cm
midcost
margin
larg
left
inguin
lymph
node
measur
cm
comput
tomographi
ct
imag
reveal
splenomegali
enlarg
periaort
celiac
retroperiton
left
inguin
lymph
node
blood
urin
cultur
collect
remain
steril
ebv
polymeras
chain
reaction
pcr
posit
copiesml
laboratori
valu
summar
tabl
core
needl
biopsi
left
inguin
lymph
node
show
chl
rs
cell
posit
epsteinbarr
encod
region
eber
situ
hybrid
ish
stain
show
predomin
macrophag
compris
tumor
background
bone
marrow
biopsi
neg
diseas
involv
positron
emiss
tomographi
pet
scan
show
diffus
hypermetabol
activ
lymph
node
diaphragm
well
focal
site
increas
osseou
uptak
consist
ann
arbor
stage
ivb
diseas
ip
risk
score
intraven
ganciclovir
initi
treatment
ebv
viremia
prior
start
chemotherapi
decis
made
begin
treatment
abvd
inpati
doxorubicin
dose
reduc
mgm
given
bilirubin
elev
date
treatment
risk
reduc
clearanc
vinblastin
bleomycin
dacarbazin
given
standard
dose
vital
sign
initi
treatment
signific
temperatur
f
heart
rate
hr
weight
kg
bodi
max
index
bmi
kgm
bodi
tabl
vasopressor
wean
within
hour
patient
extub
within
hour
bleomycin
omit
cycl
without
subsequ
complic
cycl
treatment
pet
imag
consist
complet
respons
cr
patient
remain
followup
evid
relaps
year
complet
therapi
patient
patient
year
old
diagnosi
histori
hiv
infect
treat
antiretrovir
therapi
baselin
count
cellsmm
undetect
hiv
viral
load
present
fever
short
breath
dri
cough
physic
examin
signific
dri
mucou
membran
diminish
breath
sound
bilater
enlarg
right
axillari
lymph
node
baselin
laboratori
valu
summar
tabl
ct
scan
chest
reveal
bilater
airspac
consolid
enlarg
right
axillari
lymph
node
bone
marrow
biopsi
perform
interpret
nondiagnost
necrot
granuloma
note
patient
intub
hospit
day
worsen
respiratori
statu
diagnos
acut
respiratori
distress
syndrom
bronchiolar
lavag
consist
pneumocysti
pneumonia
treatment
methylprednisolon
trimethoprimsulfamethoxazol
initi
hospit
day
patient
extub
follow
day
excision
right
axillari
lymph
node
biopsi
perform
consist
chl
patient
transfer
hospit
care
prior
bone
marrow
biopsi
review
hematopatholog
institut
read
consist
chl
extens
necrosi
scatter
fibrohistiocyt
infiltr
contain
typic
rs
cell
posit
eber
ish
numer
macrophag
present
percentag
enumer
pet
scan
show
mildli
hypermetabol
left
hilar
right
peribronchi
lymph
node
hypermetabol
postop
chang
right
axilla
patient
stage
ann
arbor
stage
ivb
given
presenc
bone
marrow
involv
ip
risk
score
oral
valgancyclovir
initi
treatment
cmv
viremia
therapi
initi
abvd
given
standard
dose
vital
sign
prior
start
treatment
signific
tabl
blood
cultur
collect
remain
steril
cefepim
initi
empir
intraven
salin
mg
hydrocortison
administ
well
hydromorphon
rigor
symptom
rapidli
improv
normal
lactat
resolut
fever
within
hour
antibiot
discontinu
hour
neg
cultur
abvd
continu
dexamethason
mg
premed
subsequ
infus
reaction
observ
pet
scan
perform
cycl
evalu
respons
show
progress
diseas
platinumbas
salvag
therapi
initi
patient
current
aliv
receiv
salvag
therapi
refractori
chl
patient
patient
year
old
initi
present
prior
histori
chronic
lymphocyt
leukemia
cll
treat
cycl
obinutuzumab
otlertuzumab
investig
protocol
complet
month
prior
present
diagnos
igvh
unmut
cll
present
bulki
lymphadenopathi
baselin
cytogenet
posit
trisomi
sole
abnorm
treatment
obinutuzumab
otlertuzumab
experienc
clinic
resolut
lymphadenopathi
physic
exam
end
therapi
evalu
month
sixth
cycl
treatment
note
daili
fever
high
f
physic
exam
show
evid
lymphadenopathi
hospit
evalu
serum
ebv
pcr
posit
copiesml
laboratori
valu
summar
tabl
blood
urin
cultur
collect
remain
steril
infecti
workup
neg
bone
marrow
biopsi
reveal
hypercellular
marrow
absent
cll
cell
morpholog
flow
cytometri
classic
rs
cell
present
posit
eber
ish
increas
surround
macrophag
pet
scan
show
hypermetabol
activ
cervic
mediastin
abdomin
pelvic
lymph
node
well
hypermetabol
liver
lesion
diffus
increas
uptak
throughout
bone
marrow
patient
stage
ann
arbor
stage
ivb
richter
transform
chl
ip
risk
score
oral
valacyclovir
initi
patient
discharg
hospit
upon
outpati
evalu
decis
made
initi
treatment
abvd
given
standard
dose
vital
sign
prior
treatment
signific
f
hr
weight
kg
bsa
bmi
bleomycin
administ
dacarbazin
complet
rigor
note
temperatur
f
inpati
admiss
request
confus
lethargi
note
f
hr
bp
rr
hydrocortison
administ
intraven
mg
well
oral
acetaminophen
normal
salin
hydrat
patient
develop
progress
hypoxia
requir
oxygen
highflow
nasal
canula
chest
radiograph
demonstr
pulmonari
edema
pattern
bilater
blood
urin
cultur
collect
remain
steril
extend
respiratori
viral
panel
return
posit
coronaviru
laboratori
valu
summar
tabl
despit
fluid
resuscit
patient
develop
progress
hypotens
norepinephrin
infus
initi
maintain
mean
arteri
bp
mg
intraven
dexamethason
administ
hypotens
quickli
improv
norepinephrin
titrat
within
hour
onset
intraven
antibiot
discontinu
blood
cultur
remain
steril
hour
oxygen
wean
within
hour
patient
discharg
hospit
day
remain
cycl
abvd
dexamethason
mg
given
day
prior
treatment
addit
mg
day
treatment
patient
experienc
rigor
home
cycl
day
took
mg
oral
dexamethason
resolut
symptom
subsequ
episod
note
patient
complet
cycl
abvd
end
therapi
pet
consist
cr
end
therapi
bone
marrow
biopsi
neg
chl
cll
within
month
relaps
cll
diagnos
bone
marrow
biopsi
patient
opt
undergo
allogen
hematopoiet
cell
transplant
hct
reducedintens
condit
haploident
relat
donor
definit
treatment
cll
mitig
risk
relaps
richter
transform
chl
remain
aliv
activ
followup
evid
relaps
cll
chl
month
hct
given
high
probabl
cure
chl
frontlin
multiag
chemotherapi
shortand
longterm
toxic
treatment
particular
import
awar
potenti
therapyrel
toxic
support
manag
essenti
case
seri
highlight
rare
lifethreaten
earli
complic
therapi
abvd
case
occur
cycl
day
abvd
therapi
patient
share
multipl
baselin
clinic
characterist
includ
advanc
stage
diseas
b
symptom
viremia
high
risk
ip
score
eberposit
diseas
baselin
characterist
summar
tabl
constel
mark
pyrexia
hypoperfus
respiratori
failur
absenc
identifi
bacteri
infect
report
rare
complic
earli
clinic
trial
singleag
bleomycin
least
case
similar
constel
symptom
lead
fatal
cardiorespiratori
collaps
patient
lymphoma
treat
bleomycin
contain
regimen
report
review
perform
regard
need
perform
test
dose
bleomycin
author
postul
lack
report
similar
episod
beyond
may
owe
routin
antiemet
corticosteroid
premed
current
bleomycincontain
regimen
prior
episod
unidentifi
contamin
longer
present
current
bleomycin
formul
sinc
time
subsequ
case
report
febril
hypotens
reaction
associ
tl
within
first
hour
first
abvd
infus
chl
report
seri
demonstr
febril
hypotens
reaction
occur
modern
bleomycin
formul
corticosteroid
premed
tl
evid
case
institut
appear
prerequisit
reaction
seri
time
onset
minut
complet
bleomycin
infus
coincid
onset
pyrexia
anim
studi
singleag
bleomycin
time
cours
similar
prior
case
report
follow
singleag
bleomycin
treatment
point
bleomycin
caus
agent
remain
possibl
agent
abvd
contributori
although
fulmin
febril
episod
fatal
mani
earli
case
report
patient
present
seri
surviv
resolut
symptom
within
hour
onset
addit
intens
support
care
patient
receiv
intraven
corticosteroid
treatment
onset
manag
summar
tabl
syndrom
clinic
indistinguish
bacteri
sepsi
patient
receiv
empir
antibiot
cultur
pend
high
fever
cardiorespiratori
collaps
neurolog
symptom
seen
seri
prior
report
similar
cytokin
releas
syndrom
cr
seen
follow
bispecif
antibodi
chimer
antigen
receptor
cell
therapi
multipl
cytokin
implic
cr
includ
interferong
monoclon
antibodi
target
receptor
axi
tocilizumab
use
cr
treatment
mark
elev
serum
note
case
report
suzuki
et
al
knowledg
tocilizumab
use
context
bleomycinassoci
febril
hypotens
reaction
case
present
seri
symptom
resolv
rapidli
follow
corticosteroid
treatment
given
rariti
syndrom
safeti
bleomycin
rechalleng
welldefin
bleomycin
omit
subsequ
cycl
patient
patient
toler
bleomycin
subsequ
cycl
increas
steroid
premed
although
bleomycin
contribut
activ
abvd
least
activ
agent
combin
regimen
safe
omit
cycl
therapi
patient
advanc
stage
diseas
neg
interim
pet
imag
substitut
brentuximab
vedotin
bleomycin
aavd
compar
abvd
patient
stage
iiiiv
chl
phase
iii
studi
result
statist
signific
improv
primari
endpoint
modifi
progressionfre
surviv
year
differ
os
time
analysi
aavd
approv
unit
state
food
drug
administr
frontlin
treatment
advanc
stage
chl
would
altern
consider
bleomycin
rechalleng
avd
therapi
advanc
stage
patient
experienc
fulmin
hyperpyrexia
cycl
abvd
share
clinic
characterist
patient
seri
may
shed
light
pathophysiolog
rare
syndrom
prior
report
patient
present
seri
febril
prior
start
therapi
present
advanc
stage
diseas
bleomycin
induc
fever
presum
cytokinemedi
stimul
one
possibl
explan
febril
patient
increas
baselin
level
key
cytokin
addit
effect
cytokin
stimul
bleomycin
cross
threshold
trigger
fulmin
reaction
common
featur
patient
seri
includ
diseas
increas
tumor
associ
macrophag
knowledg
repres
novel
observ
note
prior
case
report
major
prior
report
occur
develop
standard
care
ish
test
eber
routin
stain
thu
unknown
whether
prior
case
share
common
featur
comparison
ebvneg
chl
ebvposit
diseas
associ
gene
express
signatur
macrophag
respons
includ
upregul
regulatori
cell
type
recruit
includ
upregul
alter
cytokin
signal
upregul
ifng
tnf
febril
hypotens
syndrom
follow
bleomycin
treatment
clinic
similar
cr
syndrom
macrophag
activ
cytokin
elev
macrophag
activ
appear
central
pathogenesi
mechan
fulmin
febril
hypotens
reaction
follow
bleomycin
requir
elucid
includ
determin
role
macrophag
activ
fulmin
febril
hypotens
reaction
follow
abvd
therapi
chl
rare
lifethreaten
complic
treatment
associ
tl
prerequisit
reaction
intens
support
care
corticosteroid
treatment
patient
present
seri
surviv
reaction
resolut
symptom
within
hour
onset
clinician
awar
rare
syndrom
essenti
success
manag
author
state
conflict
interest
